Thread by @DrWilfredoM

Last month, many of us @mgh_id @bwh_id @BIDMC_IDFellows + @MassDPH came together to care for 3 patients with #monkeypox in Massachusetts and used #tecovirimat for the first time in the state. I'm excited to share our experience in @OFIDJournal.

A brief 🧵academic.oup.com/ofid/advance-a…

Key takeaways:

▶️ #tecovirimat was well-tolerated
▶️ our patients (acknowledging limitations of a 3-patient observational study) felt it improved their symptoms and paused progression of early lesions
▶️ the process of obtaining and using #Tpoxx was unnecessarily cumbersome

As #monkeypox cases increase, @US_FDA and @CDCgov should urgently make #tecovirimat readily accessible, and we should leverage lessons from #COVID19 to expedite clinical trials that establish safety, efficacy and inform delivery.

How to obtain #Tpoxx: cdc.gov/poxvirus/monke…

Delivery should be grounded in equity, where #tecovirimat is readily accessible to the places/ people most burdened by #monkeypox.

@Boghuma highlights that our experience with #Tpoxx would already be vast had it been equitably available years ago.

https://twitter.com/Boghuma/status/1550526186777972736?s=20&t=sayYdFF44a8aUhuSikraaw

For a deeper dive into #tecovirimat and the other two antivirals with activity against #monkeypox (cidofovir and brincidovir), here goes a stellar review by @EmilySiegrist4 and @JosephSassineMD in @CIDJournal (h/t @PaulSaxMD ).

…mic-oup-com.ezp-prod1.hul.harvard.edu/cid/advance-ar…

Grateful to have been part of this amazing team in advocating for these patients:

@EllenNagami, Jacob Koshy, @VictorKovac6, Letumile Moeng, @ericashenoy, David Hooper, @lmadoff, Miriam Barshak, Jennifer Johnson, Christopher Rowley, Boris Julg, Elizabeth Hohmann, @JacobLazarusMD